Prostate最新文献

{"title":"Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The Influence of Prostatic Volume.","authors":"Elizabeth Robinson, Netty Kinsella, Derfel Ap Dafydd, Joshua Shur, Aslam Sohaib, Steve Hazell, Paul Bassett, Pardeep Kumar, Erik Mayer, Declan Cahill, Samuel J Withey","doi":"10.1002/pros.24886","DOIUrl":"10.1002/pros.24886","url":null,"abstract":"<p><strong>Background: </strong>Prostate specific antigen density (PSAd) is one of the strongest predictors of clinically-significant prostate cancer (csPCa) in risk calculators. There is little evidence on the effect of prostate volume on the diagnostic performance of PSAd. Our aim was to define the diagnostic accuracy of PSAd for predicting csPCa across prostate volumes.</p><p><strong>Methods: </strong>548 patients who underwent magnetic resonance imaging (MRI) and biopsy were included in this retrospective study. Patients were grouped by prostate volume; small (≤ 30 mL), medium (> 30 to < 50 mL), large (≥ 50 mL). Sensitivity and specificity of PSAd were assessed at thresholds of ≥ 0.10, ≥ 0.15, and ≥ 0.20 ng/mL/mL for two definitions of csPCa.</p><p><strong>Results: </strong>At all PSAd thresholds and for both definitions of csPCa, there was a statistically significant and clinically-relevant difference in diagnostic performance across prostate volume groups. Sensitivity was highest in small glands, lowest in large glands; the opposite being true for specificity. Using a PSAd threshold of ≥ 0.15 ng/mL/mL, sensitivity for ISUP grade ≥ 2 PCa was 83.1%, 63.6%, and 33.3% for small, medium and large prostates (p ≤ 0.001) with specificities of 48.5%, 67.5% and 79.3%, respectively (p = 0.005).</p><p><strong>Conclusions: </strong>Diagnostic performance of PSAd varied significantly by prostate volume, and by applying a single PSAd threshold across all prostate volumes risks missing csPCa in men with larger glands, whilst performing unnecessary biopsies in those with smaller glands. Defining PSAd thresholds according to prostate volume categories can therefore improve its use as a risk predictor for csPCa.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"784-791"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Heterogeneity of Advanced Prostate Cancer by ¹⁸F-DCFPyL and ¹⁸F-FDG PET/CT in a Prospective Cohort.","authors":"GuangHao Chen, YueKai Li, ShangZhen Geng, LinChen Lv, Yong Wang, Xin Li, ShouZhen Chen, BenKang Shi","doi":"10.1002/pros.24881","DOIUrl":"10.1002/pros.24881","url":null,"abstract":"<p><strong>Purpose: </strong>¹⁸F-DCFPyL (targeted PSMA) and ¹⁸F-FDG dual-tracer PET/CT combination with next-generation sequencing was applied in a prospective cohort of men with prostate cancer to identify the clinical and genetic characteristics with heterogeneous PET/CT imaging features.</p><p><strong>Methods: </strong>104 men with documented prostate cancer underwent ¹⁸F-DCFPyL and ¹⁸F-FDG PET/CT, of which 83 underwent next-generation sequencing for detecting variation of AR, TP53, RB1, PTEN, etc. Lesions were classified into DCFPyL+FDG± lesions and DCFPyL-FDG+ lesions and analyzed for heterogeneous distribution. We divided the patients with positive lesions into DCFPyL+FDG± group and DCFPyL-FDG+ group, then compared the differences in clinical features and genetic mutations between the two groups with CRPC.</p><p><strong>Results: </strong>Overall, 92 men had positive lesions detected. By comparing lesion distribution with the DCFPyL+FDG ± , DCFPyL-FDG+ disease had higher proportions of visceral metastases (4.1% vs. 1.0%, p = 0.002). DCFPyL-FDG+ was more frequently found in CRPC cohorts, and in the CRPC cohort, patients with DCFPyL-FDG+ lesions often had worse PSA response. Exploratory analysis showed that TP53 and/or RB1 mutations might be a risk factor for DCFPyL-FDG+ disease (OR = 10.625, 95% CI 3.492-32.332, p < 0.001).</p><p><strong>Conclusion: </strong>Patients with DCFPyL-FDG+ lesions were more likely to have visceral metastases detected, be found in castration-resistant cohorts, have TP53 and/or RB1 mutations detected, and have poor therapeutic response compared to patients with DCFPyL+FDG± lesions. Therefore, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT is recommended for patients with low PSMA expression incompatible with the true burden of the disease and those with TP53 and/or RB1 mutations to better evaluate the disease burden, tumor heterogeneity, and prognosis.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"749-757"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zinc Attenuates Prostate Hyperplasia and Inflammatory Injury in Obese Rats by Regulating Zinc Homeostasis and Inhibiting the JAK1/STAT3 Pathway.","authors":"Yuanjing Li, Zongkai Wu, Jing Ma, Xuan Liu, Chenhui Zhang, JiaoYing Ma, Wen Li, Bangrong Zhao, Shusong Wang","doi":"10.1002/pros.24883","DOIUrl":"10.1002/pros.24883","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Obesity is an important risk factor for prostate damage. The importance of zinc in male reproductive spermatogenesis and the anti-inflammatory properties of zinc have been studied. However, the role of zinc in obesity-induced prostate proliferation and inflammatory injury and changes in zinc transporters are unknown and require extensive research and validation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;In this study, we modeled high-fat-fed obese rats. Then, the zinc supplementation group was given daily intragastric administration of zinc sulfate saline solution, while the control group and the high-fat group received the same amount of saline intragastric administration for 8 consecutive weeks. Sperm parameters were statistically analyzed, serum hormones were determined by chemiluminescence immunoanalyzer, and biochemical indexes were determined by automatic biochemical instrument. Inflammatory factors in prostate tissue were evaluated by enzyme-linked immunosorbent assay (ELISA), zinc content in prostate tissue was determined by inductively coupled plasma mass spectrometry (ICP-MS), and zinc transporters, inflammation and apoptosis indicators in prostate tissues were analyzed by Western Blot analysis (WB).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Result: &lt;/strong&gt;We found that obese rats had decreased sperm motility and sperm count and decreased androgens, leading to male reproductive disorders, whereas sperm motility and sperm count were increased in obese rats after zinc supplementation. The prostate epithelial cells of obese rats showed papillary proliferation with leukocyte infiltration, and the papillary proliferation of epithelial cells was alleviated after zinc supplementation. Meanwhile, pro-inflammatory cytokines and insulin growth factors IL-6, IL-1β, and IGF1 were significantly increased in prostate tissues of obese rats, whereas they were decreased after zinc supplementation. The expression of zinc transporters ZIP10 and ZIP6 was increased and the expression of ZnT3 was decreased in obese rats, while the expression of zinc transporters ZIP6 and ZIP10 was decreased and the expression of ZnT3 was increased after zinc supplementation. WB results showed that zinc supplementation reduced the expression of JAK1/STAT3, elevated the expression of caspase8, caspase3, and Bax, and decreased the expression of Bcl2. Bcl2 expression. This may be due to the fact that zinc supplementation can reduce the level of prostate inflammatory factors and insulin growth factor and promote apoptosis, thus improving prostate cell proliferation and inflammatory injury.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Zinc ameliorates prostate proliferation and inflammatory injury in obese rats by regulating zinc homeostasis, inhibiting the JAK1/STAT3 signaling pathway, and promoting apoptosis. These results provide new insights into the role of zinc as a regulator of prostate metabolism and further illustrate the potential application of zinc in male reproductive","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"767-776"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developments in Ultrasound-Based Imaging for Prostate Cancer Detection.","authors":"Reid Vassallo, Miles P Mannas, Septimiu E Salcudean, Peter C Black","doi":"10.1002/pros.24893","DOIUrl":"10.1002/pros.24893","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a significant health issue worldwide, but methods to screen for and diagnose this disease have significant inherent limitations. Some efforts to address these limitations have involved the use of ultrasound-based imaging methods.</p><p><strong>Methods: </strong>This narrative review paper focuses on recent developments in the use of medical imaging, with a focus on ultrasound and related methods, to improve the diagnosis of prostate cancer. These methods include: elastography, contrast-enhanced ultrasound, targeted contrast agents, quantitative ultrasound, multiparametric ultrasound, micro-ultrasound, and photoacoustic imaging.</p><p><strong>Results: </strong>This paper provides an update on clinically relevant imaging technologies which are in the technical and preclinical literature.</p><p><strong>Conclusion: </strong>Novel methods and their performance are highlighted, including how they address limitations in current clinical care.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"823-832"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143732608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of Subsequent Therapies After ¹⁷⁷Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.","authors":"Meryam Losee, Michael Kavanaugh, Mofei Liu, Nuno Borges, Veronica Haberman, Jolivette Ritzer, Andrew Wolanski, Sudhir Bhimaniya, Atish D Choudhury, Hyewon Hyun, Hailey Stoltenberg, Kerry L Kilbridge, Alicia Morgans, Mark Pomerantz, Matthew Robertson, Christopher Sakellis, Hina Shah, Mary-Ellen Taplin, Xiao X Wei, Thomas Ng, Praful Ravi, Heather Jacene","doi":"10.1002/pros.24880","DOIUrl":"10.1002/pros.24880","url":null,"abstract":"<p><strong>Background: </strong>¹⁷⁷Lu-vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617, LuPSMA) improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) after at least one taxane chemotherapy and androgen receptor pathway inhibitor. There are limited data on the clinical course and outcomes of patients with mCRPC after receipt of LuPSMA.</p><p><strong>Methods: </strong>We queried an IRB-approved prospectively maintained registry of all patients with mCRPC who received standard-of-care LuPSMA at our institution between June 2022 and January 2024. Clinical data about LuPSMA and subsequent therapies were extracted from the electronic medical record, including the type and number of subsequent systemic therapies, reason for treatment cessation, hematologic toxicity and supportive treatment, and PSA50 response to subsequent therapy (defined as a ≥ 50% decrease in PSA).</p><p><strong>Results: </strong>A total of 146 patients were evaluated; mean age 72 (range 52-87), observed median follow-up 5.9 months (range 0.51-18.7). Forty-four received systemic treatment after LuPSMA. The most common subsequent treatment after LuPSMA was chemotherapy (n = 27), primarily cabazitaxel ± carboplatin/cisplatin (n = 23), and the median number of cycles received was 4 (range 1-7). In 35/44 men with available hematologic toxicity data, 13 developed grade ≥ 3 anemia, 7 had ≥ grade 3 thrombocytopenia, and 16 received hematologic support. PSA50 to post-LuPSMA treatment occurred in 10/36 (28%) evaluable patients. Median overall survival from subsequent systemic therapy was 7.6 months (95% CI 5.81-NR).</p><p><strong>Conclusions: </strong>30% of patients receiving standard-of-care LuPSMA received subsequent therapy, mostly cabazitaxel-containing regimens. Post-LuPSMA treatment appeared tolerable and was associated with a PSA50 response rate of 28%. These outcomes may be biased by limited standard-of-care life-prolonging treatment options at the time of LuPSMA FDA approval, but it also highlights the continued need to develop novel therapeutic strategies for mCRPC post-LuPSMA.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"742-748"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?","authors":"Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe, Katsuki Muramoto, Takafumi Yanagisawa, Wataru Fukuokaya, Keiichiro Mori, Kojiro Tashiro, Kota Katsumi, Hidetsugu Takahashi, Kentaro Yoshihara, Keiichiro Miyajima, Yu Imai, Kosuke Iwatani, Sotaro Kayano, Taro Igarashi, Masaya Murakami, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Takahiro Kimura","doi":"10.1002/pros.24885","DOIUrl":"10.1002/pros.24885","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-specific antigen (PSA) kinetics serve as valuable surrogate markers for estimating survival outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen receptor pathway inhibitors (ARPI). While both the PSA response rate and absolute PSA value are typically assessed, determining which marker holds greater significance in real-world clinical settings is a critical clinical question. In this study, we compare the PSA response rate and absolute PSA value 3 months after the initiation of doublet ARPI therapy to identify which serves as a more effective surrogate marker in practice.</p><p><strong>Patients and methods: </strong>A total of 273 patients with mHSPC treated with ARPIs such as abiraterone acetate, enzalutamide, or apalutamide between February 2018 and June 2023 were included in this study. The study investigated PSA kinetics, including PSA levels at 3 months and the PSA response rate at 3 months. The outcome measures assessed were castration-resistant prostate cancer-free survival (CRPCFS), cancer-specific survival (CSS), and overall survival (OS).</p><p><strong>Results: </strong>The Youden index for the absolute PSA value at 3 months is 0.740 ng/mL. There is a significant difference in survival outcomes (CRPCFS, CSS, and OS) between patients with PSA levels > 0.740 ng/mL and those with ≤ 0.740 ng/mL. Additionally, the Youden index for the PSA response rate at 3 months is -99.80%. There is also a significant difference in survival outcomes (CRPCFS, CSS, and OS) between patients with response rates > -99.80% and those with rates ≤ -99.80%. In terms of clinical demographics with or without achieving PSA absolute value ≦ 0.740 ng/mL and PSA response rate ≦ -99.8%, although almost factors are different significantly (iPSA, age, PS, LN metastasis, EOD, CHAARTED criteria, LATTITUDE criteria, Hb, ALP, and LDH) between > 0.740 ng/mL and ≦ 0.740 ng/mL cohort, there are no significant difference in clinical factors other than age between > -99.80% and ≦ -99.80% cohort.</p><p><strong>Conclusion: </strong>Both the absolute value of PSA and the PSA response rate at 3 months after the initiation of ARPI can estimate survival outcomes. However, the PSA response rate is a more valuable surrogate marker for assessing treatment efficacy than the absolute PSA value. This is because the baseline clinical factors differ significantly among cohorts categorized by absolute PSA values, allowing for better predictions of survival outcomes at the start of treatment. Findings of this study could aid in decision-making following the initiation of doublet ARPI therapy within a short timeframe. Further studies are needed to validate our results.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"833-840"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate Cancer in Mice.","authors":"Xiaoli Zhang, Weicong Sang, Xiaoping Hong, Haihong Qu, Jindong Tong, Qingtong Yi","doi":"10.1002/pros.24892","DOIUrl":"10.1002/pros.24892","url":null,"abstract":"<p><strong>Background: </strong>To explore the therapeutic and preventive effect of dendritic cells injection combined with radical prostatectomy on prostate cancer in mice.</p><p><strong>Methods: </strong>We extracted antigens from mouse prostate cancer cells RM-1 and cocultured them with dendritic cells to induce maturation. We constructed in situ carcinoma and subcutaneous tumor models of the mouse prostate. The efficacy of dendritic cell injection combined with radical prostatectomy was evaluated in the carcinoma in situ model, and the ability of dendritic cells to prevent prostate cancer was evaluated in the subcutaneous tumor model. Means of assessment included ultrasonography, flow cytometry analysis, and Elisa.</p><p><strong>Results: </strong>Dendritic cell injection combined with radical prostatectomy effectively inhibited the growth of prostate carcinoma in situ in mice, as well as the growth of subcutaneous tumors of prostate cancer in mice. After dendritic cell injection, the levels of CD4 + T cells and Treg cells in the spleens of mice were significantly increased, and the levels of IL-2 and TNF-γ in the peripheral serum were significantly increased.</p><p><strong>Conclusions: </strong>Injection of mature dendritic cells induced by mouse prostate cancer cell RM-1 antigen can inhibit the growth of prostate cancer. Radical prostatectomy combined with dendritic cell injection might be a potential treatment strategy for prostate cancer.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"860-868"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prostate Microbiome Is Associated With Prostate Size and PSA Level, Independent of Age, in BPH Patients.","authors":"Alec Sun, Juan Sebastian Rodriguez-Alvarez, Shelby Harper, Prajit Khooblall, Thien Dang, Smita De, Aaron W Miller","doi":"10.1002/pros.24891","DOIUrl":"10.1002/pros.24891","url":null,"abstract":"<p><strong>Background: </strong>The etiology of benign prostatic hyperplasia (BPH) is not well understood, though recent literature suggests that the urinary tract microbiome may play a role. We aimed to examine the prostatic microbiome in BPH and its associations with patient characteristics.</p><p><strong>Methods: </strong>Men undergoing Holmium Laser Enucleation of the Prostate (HoLEP) were recruited if they were over 18 years old and had no history of prostate cancer, prostate surgery, or pelvic radiation. Exclusion criteria included positive preoperative urine culture, bladder stones, or catheter-dependence. Patient characteristics including age, prostate-specific antigen (PSA), American Urological Association symptom score (AUASS), and history of biopsy were recorded. Intraoperatively, prostate tissue was collected from each patient, as well as catheterized urine, urethral swabs, and swabs of the specimen container. Samples underwent DNA extraction, 16S sequencing, and analysis using R statistical software. Associations between bacterial taxonomic diversity and patient characteristics were quantified through Sparcc correlations.</p><p><strong>Results: </strong>Fifty patients were recruited. Mean age, PSA, prostate size, and AUASS were 67.8 years, 4.0 ng/mL, 108.6 g, and 19.4, respectively. After bioinformatic decontamination of prostate samples, alpha and beta diversity analyses indicated that microbiomes from the prostate, urethra, and urine were all distinct (p = 0.001); microbiota from the urine and urethra had higher similarity to each other than that of the prostate. Campylobacter, Caryophanaceae, Enterobacter, and Senegalimassilia positively correlated with prostate size or PSA.</p><p><strong>Conclusions: </strong>The prostatic microbiome is unique and distinct from that of urine and urethra, with several known pathogens positively correlating with prostate size and PSA.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"850-859"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI Fusion Targeted Prostate Biopsy Population.","authors":"Yuki Miura, Tohru Yoneyama, Hayato Yamamoto, Hiromu Suzuki, Takuma Otsubo, Eriko Fujita, Fumiyasu Tsushima, Shintaro Goto, Teppei Okamoto, Naoki Fujita, Masahiro Ishiyama, Tadashi Yoshizawa, Shingo Kakeda, Shingo Hatakeyama, Chikara Ohyama","doi":"10.1002/pros.24894","DOIUrl":"10.1002/pros.24894","url":null,"abstract":"<p><strong>Background: </strong>The α2,3-sialyl N-glycosylated free prostate-specific antigen ratio (S2,3PSA%) was approved in Japan as a prostate cancer (PCa) diagnostic test. We evaluated the analytical characterization and real-world diagnostic performance of S2,3PSA%.</p><p><strong>Methods: </strong>The precision testing, dilution linearity, measurement sensitivity, preanalytical stability, and interferences of S2,3PSA, α2,6-sialyl N-glycosylated free PSA (S2,6PSA), and S2,3PSA% were performed. The diagnostic accuracy detecting PCa of S2,3PSA% was prospectively evaluated in 253 men (Cohort 1, vs. PI-RADS) and in 145 men (Cohort 2, vs. PI-RADS, prostate health index, phi) who scheduled MRI-targeted biopsy by area under the receiver operating characteristics curve (AUC).</p><p><strong>Results: </strong>The precision of the S2,3PSA, S2,6PSA, and S2,3PSA% were all < 3.4% coefficient of variation. The dilution linearity of S2,3PSA had a correlation coefficient of 0.9949-0.9987. The detection limit of S2,3PSA and S2,6PSA was 0.044 and 0.029 ng/mL, respectively. Serum S2,3PSA and S2,6PSA concentrations were stable at 6°C for 24 h and -20°C for 90 days, while S2,3PSA% was unchanged at 6°C and -20°C for 90 days or under five freeze-thaw cycles. Serum S2,3PSA and S2,3PSA% were not affected by any interferences and drugs. In Cohort 1, AUC of S2,3PSA% (0.776, 95% CI 0.719-0.832) detecting PCa was comparable to that of PI-RADS (0.746, 0.685-0.807, p = 0.7996). In Cohort 2, AUC of S2,3PSA% detecting PCa (0.837, 0.774-0.901) was comparable to PI-RADS (0.779, 0.703-0.854, p = 0.3037), and phi (0.867, 0.809-0.926, p = 0.3000).</p><p><strong>Conclusions: </strong>Analytical characteristics of S2,3PSA% perform well and the diagnostic performance of S2,3PSA% was comparable to phi and MRI.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"869-887"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North-American Cohort.","authors":"Silvia Viganò, Marco Finati, Alex Stephens, Alessandro Bertini, Alessio Finocchiaro, Giovanni Lughezzani, Nicolò Buffi, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Marta Rossanese, Ettore Di Trapani, Vincenzo Ficarra, Akshay Sood, Craig Rogers, Firas Abdollah","doi":"10.1002/pros.24882","DOIUrl":"10.1002/pros.24882","url":null,"abstract":"<p><strong>Background: </strong>Socioeconomic status and geographical location contribute to disparities in localized prostate cancer (PCa) treatment. We examined the impact of area of deprivation index (ADI) on initial treatment type for localized PCa in a North-American cohort.</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients diagnosed with localized PCa, treated within Henry Ford Health (HFH), between 1995 and 2022, with available ADI-data. ADI was assigned based on residential census block group, ranked as a national deprivation percentile. Patients were categorized into three treatment-groups: radical prostatectomy (RP), radiation therapy (RT) and \"other\" treatment. Using multinomial logistic regression, we assessed ADI impact on treatment choice. After excluding patients without cT, ISUP-grade and/or PSA, we stratified by D'Amico risk-classification and repeated the regression analysis in each subgroup.</p><p><strong>Results: </strong>Among 14,204 patients, 28.4% were NHB. Median (IQR) age at diagnosis was 65 (59-71) years. Median (IQR) ADI was 58 (36-83) for overall cohort and 51 (30-74), 66 (45-91), and 62 (39-88) for RP, RT, and \"other\" groups, respectively (p < 0.0001). Multivariable analysis showed ADI as an independent predictor of treatment choice (p = 0.01): for each 10-unit increase in ADI, patients were 3% more likely to receive RT and 10% less likely to receive RP. High ADI predicted a lower likelihood of receiving initial surgery across all risk-groups (p < 0.001).</p><p><strong>Conclusions: </strong>Patients in more advantaged areas were more likely to receive RP, while those in disadvantaged areas received more RT. Recognizing how neighborhood factors affect treatment choices is crucial for improving health equity and reducing disparities in PCa outcomes.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"758-766"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143598199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}